Navigation Links
PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
Date:3/17/2011

BOSTON, March 17, 2011 /PRNewswire/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address best-practice strategic partnership models to increase operating efficiency and improve development effectiveness during the 20th Annual Partnerships in Clinical Trials conference, to be held March 30-April 1, 2011 in Phoenix, Arizona. Attendees can learn more about how PAREXEL has transformed its business to deliver a new level of strategic partnering, based on program design expertise, operational excellence, and project leadership to help clients achieve their development goals by visiting PAREXEL Booth #707 in the exhibit hall.

In two special presentations with Merck and Bristol-Myers Squibb, PAREXEL will discuss leveraging global resources and a worldwide technology infrastructure, as well as innovative approaches, to achieve significant value creation through strategic relationships:

eClinical Technology Track, March 31, 2:15 p.m.

The Evolution of CROs—Convergence of Service and Technology Providers will be presented by Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL with Lynne Germscheid, Account Management, Clinical and Regulatory Operations, Merck Research Laboratories Information Technology.

Strategic Sourcing Track, April 1, 11:00 a.m.

Committing to Two Partners—A Look at the BMS Integrated Strategic Sourcing Initiative will feature Joshua Schultz, Corporate Vice President and Strategic Account Leader, PAREXEL with Joan Millsaps, Director, Business Operations and Outsourcing Management and Cynthia Hauck, Associate Director, Outsourcing Management of Bristol-Myers Squibb.

The Partnerships in Clinical Trials program also features the following sessions by PAREXEL experts, which focus on achieving high levels of quality in clinical development to optimize outcomes:

  • eClinical Technology Track, March 31, 11:45 a.m.:  Achieve Closer Integration of Clinical Operations Data (EDC, IVRS, CTMS) to Improve Quality and Optimize Clinical Outcomes—John Humphreys, Product Director, CTMS

  • Regulatory Compliance & Quality Oversight Track, April 1, 11:00 a.m.:  Implement a Comprehensive Clinical Trial Drug Safety Program and Improve Quality from Clinical Development to Post-Approval—Ramita Tandon, Senior Portfolio Director, Late Phase

  • For more information about PAREXEL visit www.PAREXEL.com or Booth #707 during the conference. Information about Partnerships in Clinical Trials can be found at www.clinicaltrialpartnerships.com.

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

    Kim Baker/Gene CarozzaPAREXEL International

    PAN CommunicationsTel: +781-434-4409

    Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com

    Email: PAREXEL@pancomm.com
    '/>"/>

    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
    2. PAREXEL Expands Global Clinical Pharmacology Capabilities
    3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
    4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
    5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
    6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
    7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
    8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
    9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
    10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
    11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
    (Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
    (Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
    (Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
    (Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
    (Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
    (Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
    Breaking Medicine News(10 mins):